TrialClinical pharmacology in drug development2021

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator (D1PAM), in Healthy Subjects.

Darren Wilbraham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.